New angles of attack in the fight against chronic lymphocytic leukemia: the advent of novel non-chemotherapeutic agents

References

• Keating MJ, O'Brien S, Kontoyiannis D, et al Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 2002;43:1755–1762.
   PubMed Web of Science ®Google Scholar
• Abrisqueta P, Pereira A, Rozman C, et al Improving survival in patients with chronic lymphocytic leukemia (1980–2008): the Hospital Clinic of Barcelona experience. Blood 2009;114:2044–2050.
   PubMed Web of Science ®Google Scholar
• Thurmes P, Call T, Slager S, et al Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk Lymphoma 2008;49:49–56.
   PubMed Web of Science ®Google Scholar
• Rai KR, Sawitsky A, Cronkite EP, et al Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219–234.
   PubMed Web of Science ®Google Scholar
• Tam CS, O'Brien S, Wierda W, et al Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008;112:975–980.
   PubMed Web of Science ®Google Scholar
• Hallek M, Fingerle-Rowson G, Fink AM, et al First-line treatment with fludarabine, cyclophosphamide, and rituximab improves overall survival in previously untreated patients with advanced chronic lymphocytic leukemia: results of a randomized phase III trial on behalf of an international group of investigators and the German CLL Study Group. Blood 2009;114(Suppl. 1): (Abstract 535).
   Google Scholar
• Byrd JC, Rai K, Peterson BL, et al Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005;105:49–53.
   PubMed Web of Science ®Google Scholar
• Kay NE, Geyer SM, Call TG, et al Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 2007;109:405–411.
   PubMed Web of Science ®Google Scholar
• O'Brien S, Wierda WG, Faderl S, et al FCR-3 as frontline therapy for patients with chronic lymphocytic leukemia (CLL). Blood 2005;106(Suppl. 1): (Abstract 2117).
   Google Scholar
• Faderl S, Wierda W, O'Brien S, et al A phase II study of fludarabine (F), cyclophosphamide (C), and mitoxantrone (M) plus rituximab (R) (FCM-R) in previously untreated patients (pts) with CLL < =  70 years (yrs). J Clin Oncol 2006;24(Suppl.): Abstract 6607.
   PubMed Web of Science ®Google Scholar
• Faderl S, Wierda W, Ferrajoli A. Update of experience with fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline therapy for chronic lymphocytic leukemia (CLL). Blood 2007;110(Suppl. 1): (Abstract 627).
   PubMed Web of Science ®Google Scholar
• Wierda W, O'Brien S, Faderl S, et al CFAR, an active frontline regimen for high-risk patients with CLL, including those with del 17p. Blood 2008;112(Suppl. 1): (Abstract 2095).
   Google Scholar
• Parikh SA, Keating M, O'Brien S, et al Frontline combined chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab and rituximab (CFAR) in high-risk chronic lymphocytic leukemia. Blood 2009;114(Suppl. 1): (Abstract 208).
   Google Scholar
• Hallek M, Fingerle-Rowson G, Fink AM. Immunochemotherapy with fludarabine, cyclophosphamide, and rituximab (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival of previously untreated patients with advanced chronic lymphocytic leukemia (CLL). Blood 2008;112(Suppl. 1): (Abstract 325).
   Google Scholar
• Keating MJ, O'Brien S, Albitar M, et al Early results of a chemoimmuno-therapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079–4088.
   PubMed Web of Science ®Google Scholar
• Keating MJ, Kantarjian H, Talpaz M, et al Fludarabine: a new agent with major activity against CLL. Blood 1989;74:19–25.
   PubMed Web of Science ®Google Scholar
• Leporrier M, Chevret S, Cazin B, et al Randomized comparison of fludarabine, CAP, and CHOP in 938 previously untreated stage B and C CLL patients. Blood 2001;98:2319–2325.
   PubMed Web of Science ®Google Scholar
• Johnson S, Smith AG, Loffler H, et al Multicentre prospective randomized trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage CLL. The French Cooperative Group on CLL. Lancet 1996;347:1432–1438.
   PubMed Web of Science ®Google Scholar
• Rai KR, Peterson BL, Appelbaum FR, et al Fludarabine compared with chlorambucil as primary therapy for CLL. N Engl J Med 2000;343:1750–1757.
   PubMed Web of Science ®Google Scholar
• Catovsky D, Richards S, Matutes E, et al Assessment of fludarabine plus cyclophosphamide for patients with CLL (the LRF CLL4 Trial): a randomized controlled trial. Lancet 2007;370:230–239.
   PubMed Web of Science ®Google Scholar
• Rai K, Peterson BL, Appelbaum FR, et al Long-term survival analysis of the North American Intergroup Study C9011 comparing fludarabine (F) and chlorambucil (C) in previously untreated patients with chronic lymphocytic leukemia (CLL). Blood 2009;114(Suppl. 1): (Abstract 536).
   Google Scholar
• Catovsky D, Richards S, Matutes E, et al Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007;370:230–239.
   PubMed Web of Science ®Google Scholar
• Eichhorst BF, Busch R, Hopfinger G, et al Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006;107:885–891.
   PubMed Web of Science ®Google Scholar
• Flinn IW, Neuberg DS, Grever MR, et al Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 2007;25:793–798.
   PubMed Web of Science ®Google Scholar
• O'Brien SM, Kantarjian HM, Cortes J, et al Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 2001;19:1414–1420.
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-Lopez AJ, Link BK, et al Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825–2833.
   PubMed Web of Science ®Google Scholar
• Alas S, Emmanouilides C, Bonavida B. Inhibition of IL-10 by rituximab results in downregulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res 2001;7:709–723.
   PubMed Web of Science ®Google Scholar
• Chow KU, Sommerlad WD, Boehrer S, et al Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement and caspases. Haematologica 2002;87:33–43.
   PubMed Web of Science ®Google Scholar
• Di Gaetano N, Xiao Y, Erba E, et al Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 2001;114:800–809.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Peterson BL, Morrison VA, et al Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003;101:6–14.
   PubMed Web of Science ®Google Scholar
• Schulz H, Klein SK, Rehwald U, et al Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 2002;100:3115–3120.
   PubMed Web of Science ®Google Scholar
• Woyach J, Ruppert AS, Heerema NA, et al Treatment with fludarabine and rituximab produces extended overall survival (OS) and progression-free survival (PFS) in chronic lymphocytic leukemia (CLL) without increased risk of second malignancy: long-term follow up of CALGB study 9712. Blood 2009;114(Suppl. 1): (Abstract 539).
   Google Scholar
• Osterborg A, Dyer MJ, Bunjes D, et al Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 1997;15:1567–1574.
   PubMed Web of Science ®Google Scholar
• Rodig SJ, Abramson JS, Pinkus GS, et al Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res 2006;12:7174–7179.
   PubMed Web of Science ®Google Scholar
• Keating MJ, Flinn I, Jain V, et al Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002;99:3554–3561.
   PubMed Web of Science ®Google Scholar
• O'Brien S, Ravandi F, Riehl T, et al Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood 2008;111:1816–1819.
   PubMed Web of Science ®Google Scholar
• Rai KR, Freter CE, Mercier RJ, et al Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002;20:3891–3897.
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, O'Brien SM, Cortes JE, et al Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer 2003;98:773–778.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Zenz T, Winkler D. Subcutaneous alemtuzumab (Campath) in fludarabine-refractory CLL: final results of the CLL2H trial of the GCLLSG and comprehensive analysis of prognostic markers. Blood 2008;112(Suppl. 1): (Abstract 329).
   Google Scholar
• Lozanski G, Heerema NA, Flinn IW, et al Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004;103:3278–3281.
   PubMed Web of Science ®Google Scholar
• Lundin J, Kimby E, Bjorkholm M, et al Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002;100:768–773.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Skotnicki AB, Robak T. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007;25:5616–5623.
   PubMed Web of Science ®Google Scholar
• Montillo M, Cafro AM, Tedeschi A, et al Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine. Haematologica 2002;87:695–700.
   PubMed Web of Science ®Google Scholar
• O'Brien SM, Kantarjian HM, Thomas DA, et al Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 2003;98:2657–2663.
   PubMed Web of Science ®Google Scholar
• Wendtner CM, Ritgen M, Schweighofer CD, et al Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission–experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 2004;18:1093–1101.
   PubMed Web of Science ®Google Scholar
• Lin TS, Donohue KA, Lucas MS, et al Consolidation therapy with subcutaneous (SC) alemtuzumab results in severe infectious toxicity in previously untreated CLL patients who achieve a complete response (CR) after fludarabine and rituximab (FR) induction therapy: interim safety analysis of the CALGB study 10101. Blood 2007;110(Suppl. 1): (Abstract 755).
   Google Scholar
• Lin TS, Donohue KA, Byrd JC, et al Consolidation therapy with subcutaneous (SC) alemtuzumab after fludarabine and rituximab (FR) induction therapy improves the complete response (CR) rate in chronic lymphocytic leukemia (CLL) and eradicates minimal residual disease (MRD) but is associated with severe infectious toxicity: final analysis of CALGB study 10101. Blood 2009;114(Suppl. 1): (Abstract 210).
   Google Scholar
• Faderl S, Thomas DA, O'Brien S, et al Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 2003;101:3413–3415.
   PubMed Web of Science ®Google Scholar
• Faderl S, Ferrajoli A, Wierda W, et al Continuous infusion/subcutaneous alemtuzumab (Campath-1H) plus rituximab is active for patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Blood 2005;106(Suppl. 1): (Abstract 2963).
   Google Scholar
• Zent CS, Call TG, Shanafelt TD, et al Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Cancer 2008;113:2110–2118.
   PubMed Web of Science ®Google Scholar
• Elter T, Borchmann P, Schulz H, et al Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 2005;23:7024–7031.
   PubMed Web of Science ®Google Scholar
• Engert A, Gercheva L, Robak T, et al Improved progression-free survival (PFS) of alemtuzumab (Campath(R), MabCampath(R)) plus fludarabine (Fludara(R)) versus fludarabine alone as second-line treatment of patients with B-cell chronic lymphocytic leukemia: preliminary results from a phase III randomized trial. Blood 2009;114(Suppl. 1): (Abstract 537).
   Google Scholar
• Robak TR, Moiseev SI, Dmoszynska A, et al Rituximab, fludarabine and cyclophosphamide (R-FC) prolongs progression free survival in relapsed or refractory chronic lymphocytic leukemia (CLL) compared with FC alone: final results from the international randomized phase III REACH trial. Blood 2008;112(Suppl. 1): (Abstract 1).
   Google Scholar
• Elter T, James R, Stilgenbauer S, et al Chemoimmuno-therapy with fludarabine, cyclophosphamide and alemtuzumab (FC-Cam) in patients with relapsed or genetic high-risk CLL: final analysis of the CLL2L trial of the German CLL Study Group. Blood 2009;114(Suppl. 1): (Abstract 209).
   Google Scholar
• Badoux XC, Keating M, O'Brien S, et al Chemoimmunotherapy with cyclophosphomide, fludarabine, alemtuzumab and rituximab (CFAR) is effective in relapsed patients with chronic lymphocytic leukemia (CLL). Blood 2009;114(Suppl. 1): (Abstract 3431).
   Google Scholar
• Wierda W, O'Brien S, Wen S, et al Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin.Oncol 2005;23:4070–4078.
   PubMed Web of Science ®Google Scholar
• Keating M, Wierda W, Tam C, et al Long term outcome following treatment failure of FCR chemoimmunotherapy as initial therapy for chronic lymphocytic leukemia. Blood 2009;114(Suppl. 1): (Abstract 2381).
   Google Scholar
• Parikh SA, Keating M, O'Brien S, et al Frontline combined chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab and rituximab (CFAR) in high-risk chronic lymphocytic leukemia. Blood 2009;114(Suppl. 1): (Abstract 208).
   Google Scholar
• Sayala H, Moreton P, Richard JA, et al Interim report of the UKCLL02 Trial: a phase II study of subcutaneous alemtuzumab plus fludarabine in patients with fludarabine refractory CLL (on behalf of the NCRI CLL Trials Sub-Group). Blood 2005;106(Suppl. 1): (Abstract 2120).
   Google Scholar
• Pathan NI, Chu P, Hariharan K, Medication of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines. Blood 2008;111:1594–1602.
   PubMed Web of Science ®Google Scholar
• Byrd JC, O'Brien S, Flinn IW, et al Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res 2007;13:4448–4455.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Castro JE, Flinn IW, et al Lumiliximab in combination with FCR for the treatment of relapsed chronic lymphocytic leukemia (CLL): results from a phase I/II multicenter study. J Clin Oncol 2008;26:372s.
   Google Scholar
• Byrd JC, Kipps TJ, Ian W, et al Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 2010;115:489–495.
   PubMed Web of Science ®Google Scholar
• Teeling JL, French RR, Cragg MS, et al Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004;104:1793–1800.
   PubMed Web of Science ®Google Scholar
• Teeling JL, Mackus WJ, Wiegman LJ, et al The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006;177:362–371.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepretre S, Pedersen LM, et al Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 2008;111:1094–1100.
   PubMed Web of Science ®Google Scholar
• Tam CS, O'Brien S, Lerner S, et al The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. Leuk Lymphoma 2007;48:1931–1939.
   PubMed Web of Science ®Google Scholar
• Wierda WG, Kipps TG, Mayer J, et al Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010;28:1749–1755.
   PubMed Web of Science ®Google Scholar
• Wierda WG, Kipps TJ, Dürig J, et al Ofatumumab combined with fludarabine and cyclophosphamide (O-FC) shows high activity in patients with previously untreated chronic lymphocytic leukemia (CLL): results from a randomized, multicenter, international, two-dose, parallel group, phase II trial. Blood 2009;114(Suppl. 1): (Abstract 207).
   Google Scholar
• Leoni LM, Bailey B, Reifert J, et al Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008;14:309–316.
   PubMed Web of Science ®Google Scholar
• Fischer K, Stilgenbauer S, Schweighofer CD, et al Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): a multicentre phase II Trial of German CLL Study Group (GCLLSG). Blood 2008;112(Suppl. 1): (Abstract 330).
   Google Scholar
• Fischer K, Cramer P, Stilgenbauer S, et al Bendamustine combined with rituximab (BR) in first-line therapy of advanced CLL: a multicenter phase II trial of the German CLL Study Group (GCLLSG). Blood 2009;114(Suppl. 1): (Abstract 205).
   Google Scholar
• Kotla V, Goel S, Nischal S, et al Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2009;2:36.
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Miller KC, Musial L, et al Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006;24:5343–5349.
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, Lee BN, Schlette EJ, et al Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008;111:5291–5297.
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, Badoux XC, O'Brien S, et al Combination therapy with lenalidomide and rituximab in patients with relapsed chronic lymphocytic leukemia (CLL). Blood 2009;114(Suppl. 1): (Abstract 206).
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, O'Brien S, Wierda W, et al Lenalidomide as initial treatment of elderly patients with chronic lymphocytic leukemia (CLL). Blood 2008;112(Suppl. 1): (Abstract 45).
   PubMed Web of Science ®Google Scholar
• Chen C, Paul H, Xu W, et al A phase II study of lenalidomide in previously untreated, symptomatic chronic lymphocytic leukemia (CLL). Blood 2008;112(Suppl. 1): (Abstract 44).
   Google Scholar
• Ramsay AG, Johnson AJ, Lee AM, et al Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008;118:2427–2437.
   PubMed Web of Science ®Google Scholar
• Christian BA, Fischer B, Blum KA, et al Flavopiridol in chronic lymphocytic leukemia (CLL). Clin Leuk 2007;1:292–297.
   Google Scholar
• Sausville EA, Johnson J, Alley M, et al Inhibition of CDKs as a therapeutic modality. Ann NY Acad Sci 2000;910:207–222.
   PubMed Web of Science ®Google Scholar
• Senderowicz AM, Sausville EA. Preclinical and clinical development of cyclin dependent kinase modulators. J Natl Cancer Inst 2000;92:376–387.
   PubMed Web of Science ®Google Scholar
• Carlson BA, Dubay MM, Sausville EA, et al Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 1996;56:2973–2978.
   PubMed Web of Science ®Google Scholar
• Kaur G, Stetler-Stevenson M, Sebers S, et al Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J Natl Cancer Inst 1992;84:1736–1740.
   PubMed Web of Science ®Google Scholar
• Worland PJ, Kaur G, Stetler-Stevenson M, et al Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells: correlation with decreased H1 kinase activity. Biochem Pharmacol 1993;46:1831–1840.
   PubMed Web of Science ®Google Scholar
• Kitada S, Zapata JM, Andreeff M, et al Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 2000;96:393–397.
   PubMed Web of Science ®Google Scholar
• Lam LT, Pickeral OK, Peng AC, et al Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol 2001;2:0041.1–0041.11.
   Google Scholar
• Kitada S, Andersen J, Akar S, et al Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood 1998;91:3379–3389.
   PubMed Web of Science ®Google Scholar
• Chao SH, Price DH. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem 2001;276:31793–31799.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Peterson BL, Gabrilove J, et al Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805. Clin Cancer Res 2005;11:4176–4181.
   PubMed Web of Science ®Google Scholar
• Flinn IW, Byrd JC, Bartlett N, et al Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leuk Res 2005;29:1253–1257.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Lin TS, Dalton JT, et al Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high risk chronic lymphocytic leukemia. Blood 2007;109:399–404.
   PubMed Web of Science ®Google Scholar
• Lin TS, Heerema NA, Lozanski G, et al Flavopiridol (Alvocidib) induces durable responses in relapsed chronic lymphocytic leukemia (CLL) patients with high-risk cytogenetic abnormalities. Blood 2008;112:23–24.
   Web of Science ®Google Scholar
• Hanada M, Delia D, Aiello A, et al Bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 1993;82:1820–1828.
   PubMed Web of Science ®Google Scholar
• Reed JC, Kitada S, Takayama S, et al Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines. Ann Oncol 1994;5(Suppl. 1): S61–S65.
   PubMedGoogle Scholar
• Klasa RJ, Gillum AM, Klem RE. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev 2002;12:193–213.
   PubMedGoogle Scholar
• O'Brien S, Cunningham CC, Golenkov AK, et al Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. J Clin Oncol 2005;23:7697–7702.
   PubMed Web of Science ®Google Scholar
• O'Brien S, Moore JO, Boyd TE, et al Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 2007;25:1114–1120.
   PubMed Web of Science ®Google Scholar
• O'Brien S, Moore JO, Boyd TE, et al 5-Year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J Clin Oncol 2009;27:5208–5212.
   PubMed Web of Science ®Google Scholar
• Schwartz PS, Hockenbery DM. Bcl-2-related survival proteins. Cell Death Differ 2006;13:1250–1255.
   PubMed Web of Science ®Google Scholar
• Nguyen M, Marcellus RC, Roulston A, et al Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci USA 2007;104:19512–19517.
   PubMed Web of Science ®Google Scholar
• Campas C, Cosialls AM, Barragan M, et al Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells. Exp Hematol 2006;34:1663–1669.
   PubMed Web of Science ®Google Scholar
• O'Brien S, Claxton DF, Crump M, et al Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 2009;113:299–305.
   PubMed Web of Science ®Google Scholar
• Tse C, Shoemaker AR, Adickes J, et al ABT-263: a potent and orally bioavailable bcl-2 family inhibitor. Cancer Res 2008;68:3421–3428.
   PubMed Web of Science ®Google Scholar
• Roberts AW, Seymour JF, Brown JR, et al An ongoing phase 1/2a study of ABT-263; pharmacokinetics (PK), safety and anti-tumor activity in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Blood 2009;114(Suppl. 1): (Abstract 883).
   Google Scholar
• Contri A, Brunati AM, Trentin L, et al Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest 2005;115:369–378.
   PubMed Web of Science ®Google Scholar
• Amrein PC, Attar E, Takvorian T, et al Dasatinib has activity in relapsed/refractory chronic lymphocytic leukemia (CLL/SLL), a phase II trial. Blood 2008;112(Suppl. 1): (Abstract 3162).
   Google Scholar
• Friedberg JW, Sharman J, Sweetenham J, et al Inhibition of Syk with fostamatinib disodium has significant clinical activity in non Hodgkin's lymphoma and chronic lymphocytic leukemia. Blood 2010;115:2578–2585.
   PubMed Web of Science ®Google Scholar
• Hidalgo M, Rowinsky EK. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 2000;19:6680–6686.
   PubMed Web of Science ®Google Scholar
• Aleskog A, Norberg M, Nygren P, et al Rapamycin shows anticancer activity in primary chronic lymphocytic leukemia cells in vitro, as single agent and in drug combination. Leuk Lymphoma 2008;49:2333–2343.
   PubMed Web of Science ®Google Scholar
• Zent CS, LaPlant BR, Johnston PB, et al The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation. Cancer 2010;116:2201–2207.
   PubMed Web of Science ®Google Scholar
• Salles G, Morschhauser F, Cartron G, et al A phase I/II study of RO5072759 (GA101) in patients with relapsed/refractory CD20+ malignant disease. Blood 2008;112(Suppl. 1): (Abstract 234).
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Cartron G, Lamy T, et al Phase I study of RO5072759 (GA101) in relapsed/refractory chronic lymphocytic leukemia. Blood 2009;114(Suppl. 1): (Abstract 884).
   Google Scholar
• Kay NE, Bone ND, Tschumper RC, et al B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules. Leukemia 2002;16:911–919.
   PubMed Web of Science ®Google Scholar
• Molica S, Vitelli G, Levato D, et al Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukaemia. Br J Haematol 1999;107:605–610.
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, Manshouri T, Estrov Z, et al High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia. Clin Cancer Res 2001;7:795–799.
   PubMed Web of Science ®Google Scholar
• Lee YK, Shanafelt TD, Bone ND, et al VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance. Leukemia 2005;19:513–523.
   PubMed Web of Science ®Google Scholar